Are your sales reps struggling to hit their quotas? Discover the key to reliable revenue and commercial growth.The life sciences industry is facing unprecedented challenges in the new healthcare economy. The legacy sales-led model is falling short, and many companies are struggling with unreliable revenue.
The 2024 State of Life Sciences C-Suite Report reveals a sobering reality:
• Two-thirds of C-Suite executives report that less than 60% of their sales reps hit quotas in the past three consecutive quarters.
• Only 17% of respondents cite 70% or more reps meeting their quotas in the same period.
This isn't just about numbers—unreliable revenue affects your ability to innovate, grow your market cap or valuation, and ultimately improve patient outcomes. It's time for a change.
The report reveals the root causes of these challenges and provides actionable strategies for success. Our research shows that to achieve reliable revenue, you need to move away from the legacy sales-led model and embrace a more proactive, differentiated approach.
Unlock the critical insights you need to future-proof your company’s revenue and secure your market position.
Download the full report to navigate the shifting landscape and accelerate your commercial growth.
"These findings underscore the urgent need for life sciences companies to pivot from the legacy sales-led model to a proactive, differentiated commercial strategy," said Holley Miller, Founder and President of Grey Matter Marketing. "The industry's future success hinges on embracing transformational change to achieve reliable revenue, foster innovation, and meet the evolving demands of healthcare providers and patients. It's about redefining how we engage with markets and innovate within our commercial models."
Unlock the critical insights you need to future-proof your company’s revenue and secure your market leadership position. Download the full 2024 State of Life Sciences C-Suite Report now to navigate the shifting landscape and accelerate your commercial growth.
